Focus: Inquis Medical is a public-stage biotechnology company focused on venous thromboembolism treatment, specifically developing thrombectomy solutions for pulmonary embolism. The company is headquartered in Menlo Park, California with minimal disclosed operational scale.
Profile data last refreshed 21h ago · AI intelligence enriched 2w ago
Inquis Medical represents a highly speculative, early-stage opportunity suitable only for risk-tolerant professionals betting on a focused thromboembolism thesis with minimal current organizational infrastructure.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Inquis Medical
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Inquis Medical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo